PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

NICE rejects AZ’s Lynparza for metastatic prostate cancer

The UK’s National Institute for Health and Care Excellence’s (NICE) appraisal committee has chosen not to recommend AstraZeneca’s (AZ) PARP inhibitor Lynparza for BRCA-positive metastatic prostate cancer.
Lynparza (olaparib) is intended for the treatment of hormone-relapsed metastatic prostate cancer with BRCA1/2 mutations that has progressed after abiraterone or enzalutamide treatment in adults.
The current treatment for these patients includes docetaxel, cabazitaxel, or radium-223. In its draft guidance, NICE said that there is no direct cimparision of Lynparza to this current standard of care.
It added that although clinical trial evidence shows people receiving Lynparza treatment experienced improved progression-free survival and overall survival compared to people having re-treatment with abiraterone or enzalutamide, the evidence is uncertain.
This is because re-treatment with abiraterone or enzalutamide is not considered effective and is not the standard of care in the NHS.
NICE also said that it is uncertain how effective Lynparza is compared to docetaxel, cabazitaxel, or radium-223 as there is no direct comparison.
An indirect comparison suggests that Lynparza increases overall survival compared to cabazitaxel, but NICE reiterated that this is uncertain.
In addition, the cost-effectiveness estimates for Lynparza are uncertain because of the above ‘limitations’ in the clinical evidence and economic model.
This means that the estimates are higher than what NICE would usually consider an acceptable use of NHS resources.
The draft guidance is open to consultation until 26 March 2021, after which NICE will make its final recommendations for Lynparza in this indication.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026